


L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:119949 CAPLUS Full-text
 DN 140:267029
 TI Miniaturization of Cell-Based β -Lactamase-Dependent FRET Assays to Ultra-High Throughput Formats to Identify Agonists of Human Liver X Receptors
 AU Chin, Jayne; Adams, Alan D.; Bouffard, Aileen; Green, Ahren; Lacson, Raul G.; Smith, Todd; Fischer, Paul A.; Menke, John G.; Sparrow, Carl P.; Mitnaul, Lyndon J.
 CS Department of Atherosclerosis and Endocrinology, Merck Research Laboratories, Rahway, NJ, USA
 SO Assay and Drug Development Technologies (2003), 1(6), 777-787
 CODEN: ADDTAR; ISSN: 1540-658X
 PB Mary Ann Liebert, Inc.
 DT Journal
 LA English
 AB Activation of liver X receptors (LXRs) induces reverse cholesterol transport and increases high-d. lipoprotein cholesterol in vivo. Here, we describe novel, functional, homogeneous cell-based fluorescence resonance energy transfer assays for identifying agonists of LXRs using β -lactamase as the reporter gene. Stable Chinese hamster ovary cell lines expressing LXR α -GAL4 or LXR β -GAL4 fusion proteins that regulate β -lactamase transcription from upstream 7 + UAS GAL4 DNA binding sequences were generated and characterized. Synthetic and natural ligands of LXR dose-dependently activated the expression of β -lactamase in a subtype-specific manner. These assays were used to demonstrate that a 1-pyridyl hydantoin small mol. LXR synthetic ligand specifically activates LXR α receptors. The β -lactamase assays were optimized for cell d., DMSO sensitivity, and time of agonist stimulation. Clonal LXR β -GAL4- β -lactamase cells were miniaturized into an ultra high throughput (3,456-well nanoplates) screening format.
 IT **652992-38-6**
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses) (FRET assays were used to demonstrate that a 1-pyridyl hydantoin small mol. LXR synthetic ligand specifically activates LXR α receptors.)
 RN 652992-38-6 CAPLUS
 CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:101150 CAPLUS Full-text

DN 140:146124

TI Preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions

IN Jones, A. Brian; Adams, Alan D.; Green, Ahren I.; Huang, Shaei Y.; Tse, Bruno; Gutteridge, Clare E.; Cheng, Yuan

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 134 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|-----------------|----------|
| PI | WO 2004011448 | A1 | 20040205 | WO 2003-US22807 | 20030721 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | EP 1534696 | A1 | 20050601 | EP 2003-771693 | 20030721 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| | US 2005239769 | A1 | 20051027 | US 2005-522114 | 20050124 |
| PRAI | US 2002-398716P | P | 20020725 | | |
| | WO 2003-US22807 | W | 20030721 | | |
| OS | MARPAT 140:146124 | | | | |
| GI | | | | | |



AB The present invention relates to novel benzisoxazoles (shown as I; variables defined below; e.g. II) as LXR (nuclear oxysterol receptor) ligands and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed


levels of HDL cholesterol. Although the methods of preparation are not claimed, .apprx.60 example preps. of I and intermediates are included. For example, II was prepared from pyrrolidine-2,5-dione and 7-propyl-3-neopentyl-6-(3-bromopropoxy)-1,2-benzisoxazole in DMF in the presence of Cs₂CO₃ at room temperature; 7-propyl-3-neopentyl-6-(3-bromopropoxy)-1,2-benzisoxazole was prepared from 6-hydroxy-7-propyl-3-neopentyl-1,2-benzisoxazole, 1,3-dibromopropane and Cs₂CO₃ in DMF. The tested I have an IC₅₀ ≤ 2 μM for at least one of either the LXRα or LXRβ receptors employing the LXR radioligand competition scintillation proximity assays described. Examples of I tested for LXR transactivation have an EC₅₀ of <5,500 nM for at least one of LXRα or LXRβ receptor. Two examples of I were tested for their ability to increase cholesterol efflux from cultured human cells and the results are tabulated. For I: R₁ = CF₃, CH₂Me₃, Ph, C₁-6 alkyl, and C₁-2-alkylphenyl; R₂ = C₁-6 alkyl, COOR₃, CR₃R₄OR₅, CR₃R₄SR₅, and COR₃; R₃, R₄ and R₅ = H, Ph, and C₁-6 alkyl; Y is joined together with the N and the carbonyl C shown in I to which Y is resp. attached, to form a heterocyclic ring = 5-membered rings (2-oxopyrrolidin-1-yl, 2-oxoimidazolidin-1-yl, 4-oxoimidazolidin-1-yl, 2-oxothiazolidin-3-yl, 4-oxothiazolidin-1-yl), 6-membered rings (2-oxopiperidin-1-yl, 3-oxomorpholin-4-yl, 2-oxohexahydropyrimidin-1-yl, 6-oxo-1,2,3,6-tetrahydropyrimidin-1-yl, 2-oxohexahydropyrimidin-1-yl, 2-oxo-1,2,3,6-tetrahydropyrimidin-1-yl, 2-oxopiperazin-1-yl, 2-oxohexahydrotriazin-1-yl, 2-oxoazepan-1-yl), bicyclic heterocycles (phthalimido and related imides); Z = -C₁-6alkyl-, -C₁-6alkyl-O-, -C₃-6cycloalkyl-, and -C₃-6cycloalkyl-O-.

IT **652992-50-2P**, 5-Methyl-5-(2-pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(drug candidate, chromatog. resolution; preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)

RN 652992-50-2 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)



546/272.1
 514/738


IT **652992-51-3P**, (S)-5-Methyl-5-(2-pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)


RN 652992-51-3 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5-(2-pyridinyl)-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT **652992-59-1P**, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-2-one **652992-60-4P**, Methyl 2-[2-oxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-yl]propanoate **652992-82-0P**, 6-Phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione **652992-83-1P**, 5-Methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)
 RN 652992-59-1 CAPLUS
 CN 2-Imidazolidinone, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-60-4 CAPLUS
 CN 1-Imidazolidineacetic acid, α -methyl-2-oxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-, methyl ester (9CI)
 (CA INDEX NAME)




RN 652992-82-0 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, dihydro-6-phenyl-3-[3-[[7-propyl-3-

(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-83-1 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



IT **652992-23-9P**, 1-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]pyrrolidine-2,5-dione **652992-24-0P**, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]pyrrolidine-2,5-dione **652992-25-1P**, 2-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1H-isoindole-1,3(2H)-dione **652992-26-2P**, 3,3-Dimethyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]pyrrolidine-2,5-dione **652992-27-3P**, 3-Methyl-3-phenyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]pyrrolidine-2,5-dione **652992-28-4P**, 3-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]thiazolidine-2,4-dione **652992-29-5P**, 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]thiazolidine-2,4-dione **652992-30-8P**, 5,5-Dimethyl-3-[3-[[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]thiazolidine-2,4-dione **652992-31-9P**, [2,4-Dioxo-3-[3-[[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1,3-thiazolidin-5-yl]acetic acid **652992-33-1P**, 3-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-34-2P**, 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-35-3P**, 1-Methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-36-4P**, 5-(R)-Methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-37-5P**, 5,5-Dimethyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-38-6P**, 1-(2-Pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-41-1P**, 5-Methyl-5-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-

yl]oxy]propyl]imidazolidine-2,4-dione **652992-42-2P**,
 5-Methyl-5-phenyl-3-[3-[[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-43-3P**,
 5-Methyl-5-phenyl-3-[3-[[7-propyl-3-phenyl-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-44-4P**,
 5-Methyl-5-phenyl-3-[4-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]butyl]imidazolidine-2,4-dione **652992-45-5P**,
 5-Methyl-5-(3-carboxyphenyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-48-8P**,
 5-Methyl-5-(4-pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-49-9P**,
 5-Methyl-5-(3-pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-52-4P**,
 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(pyrimidin-2-yl)imidazolidine-2,4-dione **652992-53-5P**,
 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(pyrazin-2-yl)imidazolidine-2,4-dione **652992-54-6P**,
 3-[2,5-Dioxo-4-phenyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-4-yl]propanoic acid **652992-55-7P**,
 4-[5,5-Dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-yl]butanoic acid **652992-58-0P**,
 5-[5,5-Dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-yl]pentanoic acid **652992-61-5P**,
 2-[2-Oxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-yl]propanoic acid **652992-62-6P**,
 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-65-9P**,
 5,5-Dimethyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-70-6P**,
 1-[[trans-2-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]cyclohexyl]methyl]dihydropyrimidine-2,6(1H,3H)-dione **652992-72-8P**,
 1-[[trans-2-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]cyclopentyl]methyl]dihydropyrimidine-2,6(1H,3H)-dione **652992-78-4P**,
 1-[4-[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]butyl]dihydropyrimidine-2,6(1H,3H)-dione **652992-80-8P**,
 5-Phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione **652992-85-3P**,
 1,5-Dimethyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione **652992-92-2P**,
 1-Phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione **652992-96-6P**,
 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-pyridin-2-yl]dihydropyrimidine-2,4(1H,3H)-dione **652993-00-5P**,
 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5,6-dihydro-2H-1,2'-bipyrimidine-2,4(3H)-dione **652993-04-9P**,
 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5,6-dihydro-2H-1,5'-bipyrimidine-2,4(3H)-dione **652993-06-1P**,
 1-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]piperidin-2-one **652993-08-3P**,
 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]piperidin-2-one **652993-10-7P**,
 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]piperidin-2,6-dione **652993-13-0P**,
 1-[3-[[7-Propyl-3-phenyl-1,2-benzisoxazol-6-yl]oxy]propyl]piperidin-2,6-dione **652993-15-2P**,
 4-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]morpholine-3,5-dione **652993-17-4P**,
 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]piperazine-2,5-dione **652993-20-9P**,
 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1,3,5-triazinane-2,4-dione **652993-22-1P**,
 3-[3-[[7-Propyl-3-phenyl-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione


652993-23-2P, 6-Methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione
652993-24-3P, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]azepan-2-one **652993-25-4P**, 1-Phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)


RN 652992-23-9 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-24-0 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-25-1 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-26-2 CAPLUS

CN 2,5-Pyrrolidinedione, 3,3-dimethyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-27-3 CAPLUS

CN 2,5-Pyrrolidinedione, 3-methyl-3-phenyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-28-4 CAPLUS

CN 2,4-Thiazolidinedione, 3-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-29-5 CAPLUS

CN 2,4-Thiazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-30-8 CAPLUS

CN 2,4-Thiazolidinedione, 3-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]-5,5-dimethyl- (9CI) (CA INDEX NAME)




RN 652992-31-9 CAPLUS

CN 5-Thiazolidineacetic acid, 3-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 652992-33-1 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-34-2 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-35-3 CAPLUS


CN 2,4-Imidazolidinedione, 1-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-36-4 CAPLUS


CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 652992-37-5 CAPLUS

CN 2,4-Imidazolidinedione, 5,5-dimethyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-38-6 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 652992-41-1 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-5-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-42-2 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]-5-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 652992-43-3 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-5-phenyl-3-[3-[(3-phenyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-44-4 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-5-phenyl-3-[4-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]butyl]- (9CI) (CA INDEX NAME)




RN 652992-45-5 CAPLUS

CN Benzoic acid, 3-[4-methyl-2,5-dioxo-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-4-imidazolidinyl]- (9CI) (CA INDEX NAME)




RN 652992-48-8 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 652992-49-9 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 652992-52-4 CAPLUS


CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 652992-53-5 CAPLUS


CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-

benzisoxazol-6-yl]oxy]propyl]-1-pyrazinyl- (9CI) (CA INDEX NAME)




RN 652992-54-6 CAPLUS

CN 4-Imidazolidinepropanoic acid, 2,5-dioxo-4-phenyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-55-7 CAPLUS

CN 1-Imidazolidinebutanoic acid, 5,5-dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-58-0 CAPLUS

CN 1-Imidazolidinepentanoic acid, 5,5-dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-61-5 CAPLUS

CN 1-Imidazolidineacetic acid, α -methyl-2-oxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-62-6 CAPLUS

CN 2,4-Imidazolidinedione, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-65-9 CAPLUS


CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-70-6 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[[[(1R,2S)-2-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 652992-72-8 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[[(1R,2S)-2-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]cyclopentyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 652992-78-4 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[4-[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]butyl]- (9CI) (CA INDEX NAME)




RN 652992-80-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-5-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-85-3 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-1,5-dimethyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-92-2 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-1-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652992-96-6 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 652993-00-5 CAPLUS

CN [1(2H),2'-Bipyrimidine]-2,4(3H)-dione, 5,6-dihydro-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-04-9 CAPLUS

CN [1(2H),5'-Bipyrimidine]-2,4(3H)-dione, 5,6-dihydro-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-06-1 CAPLUS

CN 2-Piperidinone, 1-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-08-3 CAPLUS

CN 2-Piperidinone, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-10-7 CAPLUS

CN 2,6-Piperidinedione, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-13-0 CAPLUS

CN 2,6-Piperidinedione, 1-[3-[[3-phenyl-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-15-2 CAPLUS

CN 3,5-Morpholinedione, 4-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-17-4 CAPLUS

CN 2,5-Piperazinedione, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-20-9 CAPLUS

CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-22-1 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[3-[(3-phenyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-23-2 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-6-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 652993-24-3 CAPLUS

CN 2H-Azepin-2-one, hexahydro-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-25-4 CAPLUS

CN 2,4-Imidazolidinedione, 1-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



IT **652992-57-9P**, Ethyl 4-[5,5-dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-yl]butanoate **652992-64-8P**, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-3-(4-methoxybenzyl)imidazolidine-2,4-dione


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)


RN 652992-57-9 CAPLUS

CN 1-Imidazolidinebutanoic acid, 5,5-dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-, ethyl ester (9CI)
(CA INDEX NAME)



RN 652992-64-8 CAPLUS

CN 2,4-Imidazolidinedione, 3-[(4-methoxyphenyl)methyl]-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:314695 CAPLUS Full-text

DN 132:334473

TI Preparation of (carbamoylmethyl)pyrazinones as thrombin inhibitors

IN Sanderson, Philip E.; Lyle, Terry A.; Dorsey, Bruce D.; Stanton, Matthew G.; Staas, Donnette; Coburn, Craig; Naylor-Olsen, Adel M.; Morrisette, Matthew M.; Selnick, Harold G.; Nanterment, Philippe G.; Williams, Peter D.; Stauffer, Kenneth J.; Burgey, Christopher; Isaacs, Richard

PA Merck & Co., Inc., USA; Barrow, James, C.

SO PCT Int. Appl., 210 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|-----------------|----------|
| PI | WO 2000026211 | A1 | 20000511 | WO 1999-US25203 | 19991028 |
| | W: | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2348734 | AA | 20000511 | CA 1999-2348734 | 19991028 |
| | EP 1124822 | A1 | 20010822 | EP 1999-958684 | 19991028 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |
| | AU 747776 | B2 | 20020523 | AU 2000-15997 | 19991028 |
| | JP 2002528543 | T2 | 20020903 | JP 2000-579599 | 19991028 |
| | US 6610692 | B1 | 20030826 | US 1999-429741 | 19991028 |
| PRAI | US 1998-106417P | P | 19981030 | | |
| | WO 1999-US25203 | W | 19991028 | | |
| OS | MARPAT 132:334473 | | | | |
| GI | | | | | |



AB The (carbamoylmethyl)pyrazinones I [wherein b = NY1 or O; c = CY2 or N; d = CY3 or N; e-g = CY4 or N; Y1 and Y2 = independently H, (cyclo)alkyl, halogen, NH2, OH, or alkoxy; Y3 = H, (cyclo)alkyl, halogen, CN, NH2, or alkoxy; Y4 = independently H, alkyl, or halogen; W = H, R1, R1O2C, R1CO, R1SO2, R1(CH2)nNHCO, or (R1)2CH(CH2)nNHCO; n = 0-4; R1 = H, (un)substituted (cycloalkyl)alkyl, alkoxyalkyl, difluoroalkyl, carboxyalkyl, Ph, naphthyl, heterocyclyl, etc.; X = H or halogen; R3 = H, (cyclo)alkyl, halogen, (un)substituted Ph, acyl, heterocyclyl, CN, SMe, SOMe, or alkylsulfonyl] and its analogs were prepared I inhibited human α -thrombin and are expected to be useful as blood platelet aggregation inhibitors, thrombus formation

inhibitors, anticoagulants, and thrombolytics. Thus, 3-(2-phenylethylamino)-6-methyl-1-carboxymethylpyrazinone was amidated by 5-aminomethylindole in DMF in the presence of HOBT, EDC, and TEA to yield the (indolylmethylcarbamoylmethyl) pyrazinone II, which showed thrombin inhibitory activity with a K_i of ≤ 20 nM.


IT 267874-82-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of (heterocyclylmethylcarbamoylmethyl)pyrazinone s as thrombin inhibitors)

RN 267874-82-8 CAPLUS

CN 1(2H)-Pyrazineacetamide, 6-methyl-N-[(3-methyl-1,2-benzisoxazol-5-yl)methyl]-2-oxo-3-[[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1989:614472 CAPLUS Full-text

DN 111:214472

TI Preparation of 3-piperidinyl-1,2-benzisoxazoles as psychotic drugs

IN Antoku, Fujio; Yoshigi, Mayumi; Saji, Ikutaro; Ishizumi, Kikuo

PA Sumitomo Pharmaceuticals Co., Ltd., Japan

SO Eur. Pat. Appl., 43 pp.


CODEN: EPXXDW

DT Patent






LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------------------------------------------|------|----------|-----------------|----------|
| PI | EP 314098 | A2 | 19890503 | EP 1988-117836 | 19881026 |
| | EP 314098 | A3 | 19900103 | | |
| | EP 314098 | B1 | 19930804 | | |
| | R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | JP 01199967 | A2 | 19890811 | JP 1988-266754 | 19881021 |
| | CA 1335289 | A1 | 19950418 | CA 1988-581028 | 19881024 |
| | US 4937249 | A | 19900626 | US 1988-262575 | 19881025 |
| | AT 92489 | E | 19930815 | AT 1988-117836 | 19881026 |
| | ES 2059468 | T3 | 19941116 | ES 1988-117836 | 19881026 |
| PRAI | JP 1987-271462 | A | 19871026 | | |
| | EP 1988-117836 | A | 19881026 | | |
| OS | MARPAT 111:214472 | | | | |
| GI | | | | | |



I



AB The title compds. (I; A = CO, SO₂; when A = CO, B = Q1-Q5; when A = SO₂, B = 1,2-phenylene; R1 = R2 = H; or either one of R1, R2 = H, the other = OH, C1-5 alkyl, C2-6 alkanoyloxy; R1R2 = O; E = O, CH₂, CH₂CH₂; F = CH₂, CH₂CH₂; R3-R8 = H, C1-5 alkyl; R9-R12 = C1-5 alkyl; R11R12 = C3-5 alkylene; n = 0-2; W = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-6 hydroxyalkylene; G = H, C1-5 alkyl, C1-5 alkoxy, halo, HO) were prepared as psychotic drugs useful as highly selective neuroleptics, active also as analgesics, allergy inhibitors, and cardiovascular agents. A mixture of N-(4-bromobutyl)cyclohexane-1,2-dicarboximide, 3-(4-piperidinyl)-6-fluoro-1,2-benzisoxazole, K₂CO₃, and KI in DMF was heated 11 h at 90-100° to give 72.8% N-[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidinyl]butyl]cyclohexane-1,2-dicarboximide (II). In a test for neuroleptic activity against pos. symptoms, II suppressed the climbing behavior in mice induced by apomorphine with an ED₅₀ of 0.92 mg/kg after 1 h, vs. 1.8 and 9.4 mg/kg for chlorpromazine and tiaspirone, resp.


IT 123547-84-2P 123547-85-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as antipsychotic)

RN 123547-84-2 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, hexahydro-2-[4-[4-(6-methyl-1,2-benzisoxazol-3-yl)-1-piperidinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 123547-85-3 CAPLUS

CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-2-[4-[4-(6-methyl-1,2-benzisoxazol-3-yl)-1-piperidinyl]butyl]-, monohydrochloride, (3 α ,4 β ,7 β ,7 α)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



=> d 12; d 17; d his; log y

L2 HAS NO ANSWERS

L1 STR




Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

L7 HAS NO ANSWERS

L6 STR



G1 Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

L7 QUE ABB=ON PLU=ON L6

(FILE 'HOME' ENTERED AT 09:59:44 ON 10 NOV 2005)

FILE 'REGISTRY' ENTERED AT 09:59:53 ON 10 NOV 2005

L1 STRUCTURE UPLOADED

L2 QUE L1

L3 2 S L2

L4 76 S L2 FUL

FILE 'CAPLUS' ENTERED AT 10:00:16 ON 10 NOV 2005

L5 12 S L4

FILE 'REGISTRY' ENTERED AT 10:00:23 ON 10 NOV 2005

L6 STRUCTURE UPLOADED

L7 QUE L6

L8 2 S L7 SAM SUB=L4

L9 63 S L7 FUL SUB=L4

FILE 'CAPLUS' ENTERED AT 10:01:37 ON 10 NOV 2005

L10 4 S L9

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 10:02:26 ON 10 NOV 2005

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 20.21 | 221.11 |
| SINCE FILE | TOTAL |
| ENTRY | SESSION |
| -2.92 | -2.92 |